Clinical trials: Cataplexy

Narcolepsy With or Without Cataplexy

Single-dose Safety Study of APD916 in Healthy Volunteers

• Completed
• Age: 18 to 45 years
• Phase 1

The APD916-001 study is designed primarily to evaluate the safety and tolerability of APD916 when administered as a single dose

Trial name

NCT01093508

Testing

APD916

Where

United States

Volunteers

72 people, healthy volunteers welcome

Sponsor

Arena Pharmaceuticals